(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension - 2This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- 3Vinicultural Investigation: A Survey of \Enjoying Fine Vintages\ Wine sampling
- 4This cafe takes orders in sign language. It's cherished by the Deaf community
- 5Poland open to German troops to help secure Ukraine ceasefire
- Make your choice for the bird that catches your heart!
- Iran war triggering Easter staycation boom
- Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- Germany unveils rescue plan for struggling chemical sector
- Travels to Dream Objections in Europe
- Radiated Tortoise Faces Rapid Decline in Madagascar
- Overseeing Individual budgets Successfully
- Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- Untamed life Safe-havens All over the Planet Offering Remarkable Creature Experiences
